Open AccessPredictive Value of Clinical Judgment of Tumour Progression in Phase II Trials
Author(s) -
Nuria Kotecki,
Nicolas Penel,
Antoine Adenis,
Charles Ferté,
Stéphanie Clisant
Publication year - 2012
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0052638
Subject(s) - clinical judgment , clinical trial , medicine , predictive value , radiological weapon , appropriate use criteria , retrospective cohort study , surrogate endpoint , predictive value of tests , disease , medical physics , oncology , radiology
Background The diagnosis of tumour progression or progressive disease (PD) is a key element for designing and interpreting contemporary phase II trials. In some cases, PD is stated by the physician and is not formally confirmed by imaging. Purpose In this study, we intend to analyze the value of the PD based on clinical judgment and the risk of overestimating the occurrence of PD by clinical judgment. Methods We have conducted a single-centre retrospective study to analyse the diagnostic accuracy of this clinical judgment compared to planned imaging including all patients enrolled in our institution in phase II trials investigating systemic treatments for advanced solid tumours between January 2008 and November 2010. Results The positive predictive value (PPV) and the specificity of clinical judgment of PD was very high (>90%). Conclusions According to this study, the clinical judgment of PD is highly predictive of radiological PD as assessed, for example, by RECIST. Physicians do not overestimate PD occurence. Clinical judgment of PD could be taken into account in the definition of PD.